Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer
Eiji Kashiwagi(Johns Hopkins Medicine), Hiroshi Miyamoto(University of Rochester Medical Center)
Cited by 71
Related Papers
Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells
|Endocrine Related Cancer|2011|103
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition Up-regulates Interleukin-6 in Cancer Cells and Induces Subsequent Development of Interstitial Pneumonia
|Oncotarget|2013|42
Prostaglandin receptors induce urothelial tumourigenesis as well as bladder cancer progression and cisplatin resistance presumably via modulating PTEN expression
|British Journal of Cancer|2017|42
ATF2 promotes urothelial cancer outgrowth via cooperation with androgen receptor signaling
|Endocrine Connections|2018|33
Androgen Receptor Signaling Induces Cisplatin Resistance via Down-Regulating GULP1 Expression in Bladder Cancer
|International Journal of Molecular Sciences|2021|21